- Home
- NUVL vs GGB Comparison
NUVL vs GGB Comparison
Compare NUVL & GGB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- GGB
- Stock Information
- Founded
- NUVL 2017
- GGB 1901
- Country
- NUVL United States
- GGB Brazil
- Employees
- NUVL N/A
- GGB N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- GGB Steel/Iron Ore
- Sector
- NUVL Health Care
- GGB Industrials
- Exchange
- NUVL Nasdaq
- GGB Nasdaq
- Market Cap
- NUVL 5.6B
- GGB 5.9B
- IPO Year
- NUVL 2021
- GGB 1999
- Fundamental
- Price
- NUVL $70.46
- GGB $2.88
- Analyst Decision
- NUVL Strong Buy
- GGB Buy
- Analyst Count
- NUVL 10
- GGB 3
- Target Price
- NUVL $113.10
- GGB $5.00
- AVG Volume (30 Days)
- NUVL 594.2K
- GGB 7.8M
- Earning Date
- NUVL 05-08-2025
- GGB 04-28-2025
- Dividend Yield
- NUVL N/A
- GGB 4.84%
- EPS Growth
- NUVL N/A
- GGB N/A
- EPS
- NUVL N/A
- GGB 0.35
- Revenue
- NUVL N/A
- GGB $10,837,144,685.00
- Revenue This Year
- NUVL N/A
- GGB $8.01
- Revenue Next Year
- NUVL N/A
- GGB $4.95
- P/E Ratio
- NUVL N/A
- GGB $7.85
- Revenue Growth
- NUVL N/A
- GGB N/A
- 52 Week Low
- NUVL $61.80
- GGB $2.67
- 52 Week High
- NUVL $113.51
- GGB $4.04
- Technical
- Relative Strength Index (RSI)
- NUVL 39.36
- GGB 45.15
- Support Level
- NUVL $67.47
- GGB $2.80
- Resistance Level
- NUVL $77.93
- GGB $2.96
- Average True Range (ATR)
- NUVL 3.15
- GGB 0.07
- MACD
- NUVL -0.44
- GGB -0.01
- Stochastic Oscillator
- NUVL 26.88
- GGB 26.79
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About GGB Gerdau S.A.
Gerdau SA produces steel and steel products. The company operates in civil construction, agriculture, automotive, iron ore, exports, research and development, and home steel products sectors. It offers products such as nails, rebar, columns, billets, slabs, tribar tutor, mechanical construction bars, reinforced steel locks. The company's geographical segment includes Brazil Operations; North America Operations; South America Operations as well as Special Steel Operations. It derives majority of the revenue from the North America Operations segment.